# COVID-19  Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).

> **NIH NIH N01** · CHROMOLOGIC, LLC · 2020 · $1,499,993

## Abstract

The company proposes to develop a rapid clinical test using miRNA signatures to stratify patients diagnosed with COVID-19 by predicting likelihood of: 1) contracting ARDS related to COVID-19; 2) recovering from ARDS; or 3) mortality.  The company has identified a panel of miRNAs from 240 normal and 22 ARDS patients, which was able to accurately (>98%) predict outcomes.

## Key facts

- **NIH application ID:** 10259999
- **Project number:** 272201700012C-P00014-9999-2
- **Recipient organization:** CHROMOLOGIC, LLC
- **Principal Investigator:** NARESH MENON
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,499,993
- **Award type:** —
- **Project period:** 2017-03-01 → 2021-05-10

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10259999

## Citation

> US National Institutes of Health, RePORTER application 10259999, COVID-19  Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER). (272201700012C-P00014-9999-2). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10259999. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*